Malignant News and Research

RSS

Turns mortal heart attacks into non-mortal heart attacks -- NIH study

Three weeks of oral resveratrol or Longevinex- ingestion prior to an induced heart attack returned microRNA activity close to their pre-event levels in excised animal hearts. Among thousands of microRNA's studied, just six were attributed to exerting the majority of the gene-switching effects measured in the animal heart study - four microRNA optimally regulated by Longevinex- and two optimally by plain resveratrol.

28 Dec 2010

Arsenic agent for leukemia beneficial in treating medulloblastoma, Ewing's Sarcoma

Researchers at the Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown University Medical Center, have found that an arsenic-based agent already FDA-approved for a type of leukemia may be helpful in another hard-to-treat cancer, Ewing's Sarcoma (ES). The research, based on animal studies, also suggests the drug might be beneficial in treating medulloblastoma, a highly malignant pediatric brain cancer.

23 Dec 2010

Researchers discover protein that suppresses melanoma progression

In a breakthrough that could lead to new treatments for patients with malignant melanoma, researchers from Mount Sinai School of Medicine have discovered that a particular protein suppresses the progression of melanoma through regulation of an oncogene, or gene responsible for cancer growth. The study is published in the December 23 issue of Nature.

23 Dec 2010

UH scientist evaluates microRNAs as potential treatment strategy for ovarian cancer

The day when an ovarian cancer patient can treat her tumor with a single, painless pill instead of a toxic drug cocktail is the ultimate goal of the pioneering research of a University of Houston scientist.

22 Dec 2010

Men above age 75 with high-risk prostate cancer often under-treated

Older men with high-risk prostate cancer frequently are offered fewer - and less effective - choices of treatment than younger men, potentially resulting in earlier deaths, according to a new UCSF study.

22 Dec 2010

High LSC scores associated with adverse outcomes in AML patients

In an examination of leukemic stem cells (LSC), researchers have found that patients with acute myeloid leukemia who had higher activity of certain LSC genes had worse overall, event-free and relapse-free survival, according to a study in the December 22/29 issue of JAMA.

21 Dec 2010

Presence of CTCs may predict disease recurrence in patients with neck and head cancer

A new study suggests that the presence of tumor cells in the circulating blood of patients with squamous cell cancer of the head and neck may predict disease recurrence and reduced survival.

21 Dec 2010

Robotic surgery as effective as other minimally invasive techniques for head and neck squamous cell carcinomas

Less-invasive robotic surgery for upper airway and digestive track malignant tumors is as effective as other minimally invasive surgical techniques based on patient function and survival, according to University of Alabama at Birmingham researchers.

21 Dec 2010

Pediatric plastic surgeon reconstructs patient's jaw

Pediatric plastic surgeon Rohit Khosla, MD, had never seen a case like it: the 12-year-old boy's face ballooned with a rare, aggressive bone tumor. Although it was non-cancerous, the tumor was destroying the patient's jaw. Khosla knew he would need an innovative approach to save the boy's ability to chew.

17 Dec 2010

Scientists decipher genetic code for pediatric medulloblastoma

Scientists at the Johns Hopkins Kimmel Cancer Center have deciphered the genetic code for medulloblastoma, the most common pediatric brain cancer and a leading killer of children with cancer.

16 Dec 2010

New findings says TRIM24 protein plays active role in breast cancer formation

The recently identified TRIM24 protein plays an active role in pushing normal breast cells into rapid cell proliferation and, potentially, into breast cancer.

16 Dec 2010

Ultrasound-based diagnosis for rapid detection of benign and malignant ovarian cancer

It is crucial to differentiate between benign and malignant ovarian cysts and tumours in a fast and reliable manner. This improves the surgical management and prognosis of the patient.

16 Dec 2010

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Amoy Diagnostics announced today that its EGFR and BRAF mutation detection kits received market approval from China's State Food and Drug Administration (SFDA). The SFDA is the competent authority for regulating drugs and in vitro diagnostics in mainland China. The approval allows AmoyDx to market the EGFR and BRAF tests for clinical use in China.

15 Dec 2010

Targeting mutant BRAF can kill cancer cells, but cannot finish off melanoma

This past summer saw a revolution in melanoma therapy. Patients whose melanoma lesions contain a mutation in the BRAF gene were successfully treated with a BRAF-specific inhibitor, PLX4032. Reports of the drug trial described shrinking tumors and improved health. Yet seven months after therapy began the tumors returned and resumed growing. Now, scientists at The Wistar Institute explain why: the tumor learns to signal around the blocked gene by adjusting its molecular wiring.

15 Dec 2010

BSGI/MBI provides additional information when conventional imaging is indeterminate in diagnosing breast cancer

Dr. Barbara Ward and others of Weinstein Imaging determined that Breast-Specific Gamma Imaging/Molecular Breast Imaging (BSGI/MBI) provides additional information when conventional imaging is indeterminate and greater confidence is required to improve diagnostic accuracy. The data from the retrospective study demonstrated that BSGI contributed significantly to patient management by detecting cancer in 7 of the 73 patients (9%), and was presented last week at the San Antonio Breast Cancer Symposium.

15 Dec 2010

Tumor suppressor p53 may serve as 'Guardian against Genome Reprogramming'

A close collaboration between researchers at the Salk Institute for Biological Studies and the Institute for Advanced Study found that the tumor suppressor p53, long thought of as the "Guardian of the Genome," may do more than thwart cancer-causing mutations. It may also prevent established cancer cells from sliding toward a more aggressive, stem-like state by serving as a "Guardian against Genome Reprogramming."

15 Dec 2010

FP/TMEM127 gene germline mutations associated with adrenal gland tumors

Analysis has identified variations of a gene that are associated with a type of tumor that forms within the adrenal gland, according a study in the December 15 issue of JAMA. The age group in which these variations were found are frequently excluded from genetic screening models for this type of tumor.

15 Dec 2010

Program reduces cervical cancer deaths among HIV-infected women in Zambia

A new study undertaken in Zambia shows that, using setting-appropriate human resources and technology, morbidity and mortality from cervical cancer among HIV-infected women can be reduced. The study’s lead author is Dr Groesbeck Parham, Professor of Gynecologic Oncology and Infectious Diseases, University of Alabama at Birmingham, and Director of the Centre for Infectious Disease Research in Zambia’s Cervical Cancer Prevention Program. The research was published in the December issue of HIV Therapy.

14 Dec 2010

Tolerx commences TRX518 Phase 1 trial in malignant melanoma

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.

14 Dec 2010

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

Multiple myeloma, a type of blood cancer in which malignant plasma cells are overproduced in the bone marrow, has led to an estimated 20,000 new diagnoses and 11,000 deaths in 2010. Patients with the disease, who have already failed previous treatments, may be considered for a currently enrolling Phase II study, examining a unique drug combination.

14 Dec 2010

Malignant News and Research

Turns mortal heart attacks into non-mortal heart attacks -- NIH study

Arsenic agent for leukemia beneficial in treating medulloblastoma, Ewing's Sarcoma

Researchers discover protein that suppresses melanoma progression

UH scientist evaluates microRNAs as potential treatment strategy for ovarian cancer

Men above age 75 with high-risk prostate cancer often under-treated

High LSC scores associated with adverse outcomes in AML patients

Presence of CTCs may predict disease recurrence in patients with neck and head cancer

Robotic surgery as effective as other minimally invasive techniques for head and neck squamous cell carcinomas

Pediatric plastic surgeon reconstructs patient's jaw

Scientists decipher genetic code for pediatric medulloblastoma

New findings says TRIM24 protein plays active role in breast cancer formation

Ultrasound-based diagnosis for rapid detection of benign and malignant ovarian cancer

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Targeting mutant BRAF can kill cancer cells, but cannot finish off melanoma

BSGI/MBI provides additional information when conventional imaging is indeterminate in diagnosing breast cancer

Tumor suppressor p53 may serve as 'Guardian against Genome Reprogramming'

FP/TMEM127 gene germline mutations associated with adrenal gland tumors

Program reduces cervical cancer deaths among HIV-infected women in Zambia

Tolerx commences TRX518 Phase 1 trial in malignant melanoma

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News